Cryolife FibRx bioadhesive clinicals to begin by "early fall," CEO Anderson predicts.
This article was originally published in The Gray Sheet
Executive Summary
CRYOLIFE FIBRX BIOADHESIVE U.S. CLINICAL TRIALS expected to begin in late summer or early fall of this year, Cryolife President and CEO Steven Anderson told analysts May 25 at a meeting of the New York Society of Security Analysts in New York City. The study will evaluate the ability of the biodegradable bioadhesive to improve healing of skin grafts for second- and third-degree burns.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.